Verheijen J, Tahata S, Kozicz T, Witters P, Morava E. Therapeutic approaches in congenital Problems of Glycosylation (CDG) involving N-linked glycosylation: an replace. Genet Med. 2020;22:268–79.
Francisco R, Marques-da-Silva D, Brasil S, Pascoal C, Dos Reis Ferreira V, Morava E, Jaeken J. The problem of CDG prognosis. Mol Genet Metab. 2019;126:1–5.
Cherepanova N, Shrimal S, Gilmore R. N-linked glycosylation and homeostasis of the endoplasmic reticulum. Curr Opin Cell Biol. 2016;41:57–65.
Roth J, Zuber C, Park S, Jang I, Lee Y, Kysela KG, Le Fourn V, Santimaria R, Guhl B, Cho JW. Protein N-glycosylation, protein folding, and protein high quality management. Mol Cells. 2010;30:497–506.
Vilas A, Yuste-Checa P, Gallego D, Desviat LR, Ugarte M, Perez-Cerda C, Gamez A, Perez B. Proteostasis regulators as potential rescuers of PMM2 exercise. Biochim Biophys Acta Mol Foundation Dis. 2020;1866:165777.
Gao XD, Nishikawa A, Dean N. Bodily interactions between the Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticulum. Glycobiology. 2004;14:559–70.
Albright CF, Robbins RW. The sequence and transcript heterogeneity of the yeast gene ALG1, a necessary mannosyltransferase concerned in N-glycosylation. J Biol Chem. 1990;265:7042–9.
Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, Van Schaftingen E. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein kind I syndrome (Jaeken syndrome). Nat Genet. 1997;16:88–92.
Zhang W, James PM, Ng BG, Li X, Xia B, Rong J, Asif G, Raymond Ok, Jones MA, Hegde M, et al. A novel N-Tetrasaccharide in sufferers with congenital Problems of Glycosylation, together with asparagine-linked glycosylation protein 1, phosphomannomutase 2, and mannose phosphate isomerase deficiencies. Clin Chem. 2016;62:208–17.
Quelhas D, Quental R, Vilarinho L, Amorim A, Azevedo L. Congenital dysfunction of glycosylation kind Ia: looking for the origin of frequent mutations in PMM2. Ann Hum Genet. 2007;71:348–53.
Moravej H, Altassan R, Jaeken J, Enns GM, Ellaway C, Balasubramaniam S, De Lonlay P, Coman D, Mercimek-Andrews S, Witters P, Morava E. Hypoglycemia in CDG sufferers as a consequence of PMM2 mutations: comply with up on hyperinsulinemic sufferers. JIMD Rep. 2020;51:76–81.
Ng BG, Shiryaev SA, Rymen D, Eklund EA, Raymond Ok, Kircher M, Abdenur JE, Alehan F, Midro AT, Bamshad MJ, et al. ALG1-CDG: medical and molecular characterization of 39 unreported sufferers. Hum Mutat. 2016;37:653–60.
Peanne R, de Lonlay P, Foulquier F, Kornak U, Lefeber DJ, Morava E, Perez B, Seta N, Thiel C, Van Schaftingen E, et al. Congenital problems of glycosylation (CDG): Quo vadis? Eur J Med Genet. 2018;61:643–63.
Al Teneiji A, Bruun TU, Sidky S, Cordeiro D, Cohn RD, Mendoza-Londono R, Moharir M, Raiman J, Siriwardena Ok, Kyriakopoulou L, Mercimek-Mahmutoglu S. Phenotypic and genotypic spectrum of congenital problems of glycosylation kind I and sort II. Mol Genet Metab. 2017;120:235–42.
Mousa J, Veres L, Mohamed A, De Graef D, Morava E. Acetazolamide therapy in late onset CDG kind 1 as a consequence of biallelic pathogenic DHDDS variants. Mol Genet Metab Rep. 2022;32:100901.
Bruneel A, Cholet S, Drouin-Garraud V, Jacquemont ML, Cano A, Megarbane A, Ruel C, Cheillan D, Dupre T, Vuillaumier-Barrot S, et al. Complementarity of electrophoretic, mass spectrometric, and gene sequencing strategies for the prognosis and characterization of congenital problems of glycosylation. Electrophoresis. 2018;39:3123–32.
Hipgrave Ederveen AL, de Haan N, Baerenfaenger M, Lefeber DJ, Wuhrer M. Dissecting whole plasma and protein-specific glycosylation profiles in congenital Problems of Glycosylation. Int J Mol Sci. 2020;21:7635.
Abu Bakar N, Lefeber DJ, van Scherpenzeel M. Scientific glycomics for the prognosis of congenital problems of glycosylation. J Inherit Metab Dis. 2018;41:499–513.
Witters P, Edmondson AC, Lam C, Johnsen C, Patterson MC, Raymond KM, He M, Freeze HH, Morava E. Spontaneous enchancment of carbohydrate-deficient transferrin in PMM2-CDG with out mannose noticed in CDG pure historical past examine. Orphanet J Uncommon Dis. 2021;16:102.
Bengtson P, Ng BG, Jaeken J, Matthijs G, Freeze HH, Eklund EA. Serum transferrin carrying the xeno-tetrasaccharide NeuAc-Gal-GlcNAc2 is a biomarker of ALG1-CDG. J Inherit Metab Dis. 2016;39:107–14.
Jia JX, Kalisa NY, Lu TT, Zhou Z, Gao XD, Wang N. Chemo-enzymatic synthesis of the ALG1-CDG biomarker and analysis of its immunogenicity. Bioorg Med Chem Lett. 2020;30:127614.
de Morais FAP, Goncalves RS, Vilsinski BH, de Oliveira EL, Rocha NL, Hioka N, Caetano W. Hypericin photodynamic exercise in DPPC liposome. PART I: biomimetism of loading, location, interactions and thermodynamic properties. J Photochem Photobiol B. 2019;190:118–27.
Khatun F, Toth I, Stephenson RJ. Immunology of carbohydrate-based vaccines. Adv Drug Deliv Rev. 2020;165–166:117 – 26.
Yang F, Zheng XJ, Huo CX, Wang Y, Zhang Y, Ye XS. Enhancement of the immunogenicity of artificial carbohydrate vaccines by chemical modifications of STn antigen. ACS Chem Biol. 2011;6:252–59.
Yao L, Wu L, Wang R, Liu Y, Luo F, Zhang Y, Chen G. Liposome-Primarily based Carbohydrate Vaccine for concurrently eliciting Humoral and Mobile Antitumor Immunity. ACS Macro Lett. 2022;11:975–81.
Rao M, Peachman KK, Alving CR. Liposome Formulations as Adjuvants for vaccines. Curr Prime Microbiol Immunol. 2021;433:1–28.
Pifferi C, Berthet N, Renaudet O. Cyclopeptide scaffolds in carbohydrate-based artificial vaccines. Biomater Sci. 2017;5:953–65.
Peri F. Clustered carbohydrates in artificial vaccines. Chem Soc Rev. 2013;42:4543–56.
Bai L, Deng S, Reboulet R, Mathew R, Teyton L, Savage PB, Bendelac A. Pure killer T (NKT)-B-cell interactions promote extended antibody responses and long-term reminiscence to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A. 2013;110:16097–102.
Saez de Guinoa J, Jimeno R, Gaya M, Kipling D, Garzon MJ, Dunn-Walters D, Ubeda C, Barral P. CD1d-mediated lipid presentation by CD11c(+) cells regulates intestinal homeostasis. EMBO J. 2018;37:e97537.
Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted pure killer T cells. Semin Immunol. 2010;22:68–78.
Griewank KG, Lorenz B, Fischer MR, Boon L, Lopez Kostka S, von Stebut E. Immune modulating results of NKT cells in a physiologically low dose Leishmania main an infection mannequin after alphaGalCer analog PBS57 stimulation. PLoS Negl Trop Dis. 2014;8:e2917.
Maia ML, Pereira CS, Melo G, Pinheiro I, Exley MA, Porto G, Macedo MF. Invariant pure killer T cells are lowered in Hereditary Hemochromatosis Sufferers. J Clin Immunol. 2015;35:68–74.
Szoka F Jr, Papahadjopoulos D. Comparative properties and strategies of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9:467–508.
Deng S, Bai L, Reboulet R, Matthew R, Engler DA, Teyton L, Bendelac A, Savage PB. A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a pure killer T cell antigen, generates sturdy antibody responses in vivo. Chem Sci. 2014;5:1437–41.
Yeh HW, Lin TS, Wang HW, Cheng HW, Liu DZ, Liang PH. S-Linked sialyloligosaccharides bearing liposomes and micelles as influenza virus inhibitors. Org Biomol Chem. 2015;13:11518–28.
Liao G, Zhou Z, Suryawanshi S, Mondal MA, Guo Z. Totally artificial self-adjuvanting alpha-2,9-Oligosialic acid primarily based Conjugate vaccines towards Group C Meningitis. ACS Cent Sci. 2016;2:210–8.
Bachmann MF, Jennings GT. Vaccine supply: a matter of measurement, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787–96.
Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari MR. Influence of particle measurement and Polydispersity Index on the medical purposes of Lipidic Nanocarrier Techniques. Pharmaceutics. 2018;10:57.
Gopi S, Balakrishnan P. Analysis and medical comparability research on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability. J Liposome Res. 2021;31:356–64.
Singh AK, Gaur P, Das SN. Pure killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions. Hum Immunol. 2014;75:250–60.
Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L. Glycolipid antigen induces long-term pure killer T cell anergy in mice. J Clin Make investments. 2005;115:2572–83.
Yin XG, Lu J, Wang J, Zhang RY, Wang XF, Liao CM, Liu XP, Liu Z, Guo J. Synthesis and analysis of liposomal Anti-GM3 Most cancers vaccine candidates covalently and noncovalently adjuvanted by alphaGalCer. J Med Chem. 2021;64:1951–65.
Iyoda T, Ushida M, Kimura Y, Minamino Ok, Hayuka A, Yokohata S, Ehara H, Inaba Ok. Invariant NKT cell anergy is induced by a robust TCR-mediated sign plus co-stimulation. Int Immunol. 2010;22:905–13.
Lam JH, Smith FL, Baumgarth N. B cell activation and response regulation throughout viral infections. Viral Immunol. 2020;33:294–306.
Schmid H, Schneidawind C, Jahnke S, Kettemann F, Secker KA, Duerr-Stoerzer S, Keppeler H, Kanz L, Savage PB, Schneidawind D. Tradition-expanded human invariant pure killer T cells suppress T-Cell alloreactivity and eradicate leukemia. Entrance Immunol. 2018;9:1817.
Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, Pillai S, Besra GS, Brenner MB. NK T cells present lipid antigen-specific cognate assist for B cells. Proc Natl Acad Sci U S A. 2008;105:8339–44.
Mai Y, Guo J, Zhao Y, Ma S, Hou Y, Yang J. Intranasal supply of cationic liposome-protamine advanced mRNA vaccine elicits efficient anti-tumor immunity. Cell Immunol. 2020;354:104143.
Wang N, Chen M, Wang T. Liposomes used as a vaccine adjuvant-delivery system: from fundamentals to medical immunization. J Management Launch. 2019;303:130–50.
Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50:3–20.
Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q. Virus-like particle (VLP) lymphatic trafficking and immune response technology after immunization by totally different routes. J Immunother. 2009;32:118–28.
Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP. Nanoparticle vaccines. Vaccine. 2014;32:327–37.
Kim H, Uto T, Akagi T, Baba M, Akashi M. Amphiphilic poly(amino acid) nanoparticles induce size-dependent dendritic cell maturation. Adv Funct Mater. 2010;20:3925–31.
Okuda T, Fukui A. Era of anti-oligosaccharide antibodies that acknowledge mammalian glycoproteins by immunization with a novel synthetic glycosphingolipid. Biochem Biophys Res Commun. 2018;497:983–9.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from construction to effector capabilities. Entrance Immunol. 2014;5:520.
Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. TLR signaling fine-tunes anti-influenza B cell responses with out regulating effector T cell responses. J Immunol. 2007;178:2182–91.
Martin RM, Brady JL, Lew AM. The necessity for IgG2c particular antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Strategies. 1998;212:187–92.
Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass exercise by selective fc receptor binding. Science. 2005;310:1510–2.
Zhou Z, Liao G, Mandal SS, Suryawanshi S, Guo Z. A completely artificial self-adjuvanting Globo H-Primarily based vaccine elicited robust T cell-mediated Antitumor Immunity. Chem Sci. 2015;6:7112–21.
Ramirez AS, Boilevin J, Lin CW, Ha Gan B, Janser D, Aebi M, Darbre T, Reymond JL, Locher KP. Chemo-enzymatic synthesis of lipid-linked GlcNAc2Man5 oligosaccharides utilizing recombinant Alg1, Alg2 and Alg11 proteins. Glycobiology. 2017;27:726–33.
